Shawn Noronha, Yue Liu, Gaga Geneti, Hongchuan Li, Xiao‐Lin Wu, David Sun, Vaibhavi Gujar, Takashi Furusawa, Alexei Lobanov, Maggie Cam, Lipika R. Pal, Nishanth Ulhas Nair, Chi‐Ping Day, Eytan Ruppin, Chandrayee Gosh, Jiangnan Hu, Bhavishya Ramamoorthy, Suresh Kumar, Þorkell Andrésson, King C. Chan, Maura O’Neill, Raj Chari, Yves Pommier, Jaydira Del Rivero, Urbain Weyemi, Electron Kebebew, Myriem Boufraqech
Anaplastic thyroid cancer (ATC) is the most aggressive form of thyroid cancer. Despite recent advances in treating BRAFV600E-driven ATC, therapy resistance remains a significant challenge, often resulting in disease progression and death. Leveraging a focused CRISPR/KO screen in parallel with a CRISPR/activation screen, both tailored on response to BRAFV600E inhibitor treatment, we identified TAZ (encoded by WWTR1 gene) deficiency as synthetically lethal with BRAF inhibitor in ATC. TAZ is overexpressed in ATC compared to well-differentiated thyroid tumors. We demonstrate that TAZ-deficient ATC cells display heightened sensitivity to BRAF inhibitors. Using gene essentiality score across cancer cell lines, we found that BRAFV600E-driven cancers are highly sensitive to TAZ loss, unlike their counterparts with wild-type BRAF and non-BRAFV600E. Mechanistically, we demonstrate that dabrafenib triggers the Unfolded Protein Response (UPR) under ER stress and suppresses protein synthesis. TAZ loss represses the UPR, reverses the inhibition of protein synthesis, and triggers increased cell death by ferroptosis in dabrafenib-treated ATC. Collectively, our findings unveil TAZ as a new target to overcome resistance to BRAF inhibitors in undifferentiated thyroid cancer.